Precision Medicine
==================

Since the completion of the Human Genome Project, DNA sequencing technologies have been advancing rapidly ([@B43]; [@B37]). These advances have been most notable in terms of a dramatic decrease in the cost per base pair sequenced ([@B78]). This has led to an exponential increase in the abundance of individual-specific genotype data and other forms of human biological "omics" information ([@B43]; [@B86]). As a result of these technological developments, the concept of precision medicine, or personalized medicine, has undergone a world-wide upsurge in support as a way of transforming disease prediction, prognosis, and individual participation in preventative strategies ([@B43]; [@B37]).

The objective of precision medicine is to deliver tailored medical treatments for patients according to their genetic characteristics. This primarily involves customizing proactive and preventive care to maximize medical efficacy and cost-effectiveness ([@B43]). Personalization is achieved by integrating and utilizing various types of omics information to generate and understand disease risks ([@B43]; [@B86]; [@B69]). The application of precision medicine to pharmacogenomics has allowed for customized drug and dosage use with considerable success. For example, genetic information is regularly incorporated into treatment strategies for trastuzumab treatment for HER2-positive breast cancers, erlotinib for EGFR-overexpressing lung cancers, or imatinib for Philadelphia chromosome-positive chronic myelogenous leukaemias ([@B73]; [@B94]). However, in the context of population health, it is hotly debated whether precision genomics is yet at a point where it offers cost-benefits over and above fully implemented standard public health approaches.

Genome-Wide Association Studies
===============================

There are millions of single nucleotide polymorphisms (SNPs, also known as genetic variants) in each human genome ([@B9]). Genome-wide association (GWA) studies identify SNPs that mark genomic regions that are strongly associated with phenotypes in a population ([@B92]). These genomic regions must contain the variant that is causally associated with the phenotype, however it does not follow that the SNP that is identified by the GWA study is causal. Notably, many common and complex diseases \[e.g., type 2 diabetes (T2D) and obesity\] are influenced by multiple SNPs, each with small per-SNP effect sizes ([@B93]). Of note, the majority of these SNPs are located in non-coding regions and thus must be indirectly involved in their disease association, likely through tissue-specific regulatory activities ([@B93]; [@B76]). New methods to understand these regulatory activities include the integration of spatial and temporal aspects of gene expression data ([@B77]; [@B75]; [@B27], [@B28]; [@B56]). These approaches are providing insights into the impacts of genetic variants that can reassign population based risk to individualized risk.

Predicting Risk Scores and AUC
==============================

Traditional epidemiology based models of disease risk (with limited predictive power) have been primarily informed by lifestyle risk factors such as family history ([@B39]; [@B95]). Recently, the inclusion of genetic risk factors, including disease or phenotype associated SNPs, into risk modeling has improved the accuracy of individual disease prediction ([@B39]; [@B95]). Perhaps the greatest promise of risk prediction models lies in their potential to guide diease prevention and treatment without the need for costly and potentially adverse medical screening procedures (e.g., invasive biopsies) ([@B100]; [@B7]; [@B47]; [@B1]).

Currently, the main focus of developing genetic risk models is to achieve accurate predictive power for recognizing at-risk individuals in a robust manner ([@B7]; [@B47]; [@B52]). As stated earlier, GWA studies define SNPs according to their association with a disease/phenotype at a population level. Therefore, the incorporation of SNPs into a risk prediction model requires integration into models that score an individual's genotype to enable the estimation of risk. Genetic risk prediction models are typically constructed by: (1) Polygenic risk scoring; or (2) Machine learning ([@B97]; [@B1]). The predictive performance of both model types is evaluated by receiver operating characteristic curves (ROCs) ([@B40]; [@B39]; [@B91]; [@B95]), where the sensitivity and specificity of the predictions are ranked at various cut-off values ([@B40]; [@B39]; [@B90]; [@B95]). The area under a ROC curve (AUC) is the probability of the examined model correctly identifying a case out of a randomly chosen pair of case and control samples ([@B40]; [@B39]; [@B41]; [@B90]; [@B95]). AUC results range from 0.5 (i.e., random) to 1 (i.e., 100 percent accuracy) ([@B40]; [@B39]; [@B90]; [@B95]).

Polygenic Risk Scoring
======================

Polygenic risk scoring uses a fixed model approach to sum the contribution of a set of risk alleles to a specific complex disease ([@B10]; [@B16]; [@B95]; [@B84]). Polygenic risk scores can be unweighted or weighted. In weighted polygenic risk scores, the contributions of the risk alleles is typically weighted by their odds ratios or effect sizes ([@B26]; [@B65]; [@B97]; [@B14]; [@B48]). By contrast, unweighted polygenic risk scores are equal to the sum of the number of associated variant alleles in a genome. The unweighted model assumes that all variants have an equivalent effect size ([@B14]; [@B1]; [@B34]). This simplistic assumption limits the utility of unweighted polygenic risk scores for complex traits with underlying genetic architectures that include uneven variant effects ([@B14]; [@B1]; [@B34]).

There are two stages to the development of a polygenic risk score: (1) the discovery stage; and (2) the validation stage. The discovery stage of a weighted polygenic risk score uses statistical association testing (e.g., linear or logistic regression) to estimate effect sizes from a large case and control dataset of individual genotype profiles ([@B26]; [@B16]; [@B24]). The discovery stage of an unweighted polygenic risk score requires strict SNP selection parameters to prevent incorporation of SNPs with minor effect sizes. In both the weighted and unweighted polygenic risk score, once developed, the discovery model is passed to the validation stage. Validation of the polygenic risk score requires the extraction of informative SNP identities and effect sizes from the discovery set, using a stringent association *p*-value threshold (e.g., 5 × 10^-8^) ([@B24]; [@B101]),which is subsequently passed to a scoring phase of the validation. During this process, the polygenic risk score model is applied to a testing dataset \[i.e., an independent set of case and control genotype data ([@B16]; [@B24])\]. Polygenic risk scores are calculated for each individual genotype profile in the testing data ([@B16]; [@B24]). The predictive power of the individual polygenic risk scores for the complex trait are then established by the strength of the score associations with the clinically measured outcomes (phenotypes) in the testing dataset ([@B16]; [@B24]).

Early attempts to use weighted polygenic risk scores, were based on small numbers of highly significant SNPs identified from GWA studies, and achieved only limited predictive value for complex diseases ([@B5]; [@B24]). This illustrates a key limitation of weighted polygenic risk score modeling, specifically the *p*-value threshold for SNP choice in the discovery dataset impacts on the model's performance and predictive power. The selection of limited numbers of SNPs, with large effect sizes, over-simplifies the biological underpinnings of the complex diseases by ignoring the bulk of the variants that make much smaller individual contributions to the phenotype ([@B93]). For example, the average odds ratio per T2D risk allele ranges from 1.02 to 1.35 ([@B81]). Recent polygenic risk score models incorporate expanded SNP selection to achieve better predictive results for complex polygenic traits ([@B24]; [@B25]; [@B84]). For example, the use of relaxed *p*-value thresholds (as high as 0.01, 0.1, and 0.2 etc...) has enabled the development of improved polygenic risk score models for psychiatric diseases, with minimal increases in false positive errors (i.e., the models have an acceptable power-to-noise ratio) ([@B5]; [@B40]; [@B101]). The weighted polygenic risk score approach has enabled the risk prediction of schizophrenia to achieve reasonable efficacy with an AUC of ∼0.65 ([@B39]). Similarly, significant results from weighted polygenic risk score predictions were also obtained for other complex traits including Type 1 diabetes and celiac disease (CD) ([@B39]; [@B101]; [@B84]).

Machine Learning Disease Prediction Models
==========================================

Machine learning approaches adapt a set of sophisticated statistical and computational algorithms (e.g., Support vector machine (SVM) or Random forest) to make predictions by mathematically mapping the complex associations between a set of risk SNPs to complex disease phenotypes ([@B67]; [@B97]; [@B41]; [@B51]). These methods use supervised or unsupervised approaches to map the associations with complex diseases ([@B23]). Despite the utility of unsupervised machine learning methods and non-genetic data in disease predictions ([@B83]; [@B99]), we will focus the remainder of this manuscript on supervised modeling that is informed by SNP data.

Supervised machine learning disease prediction models are generated by training the pre-set learning algorithms to map the relationships between individual sample genotype data and the associated disease ([@B23]; [@B58]). Optimal predictive power for the target disease is achieved by mapping the pattern of the selected features (variables) within the training genotype data ([@B67]; [@B51]; [@B58]). Some models use gradient descent procedures and iterative rounds of parameter estimation to search through the training data space for optimized predictive power ([@B107]; [@B49]). This recursive process continues until the optimal predictive performance is reached ([@B107]; [@B49]). At the end of the training stage, the models with the maximum predictive power on the training dataset are selected for validation ([@B90]; [@B1]). A generalized workflow for creating a machine learning model from a genotype dataset is illustrated in [Figure 1](#F1){ref-type="fig"}.
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During the validation stage, the performance of the predictive machine learning models is evaluated to determine their power for generalized prediction. As with polygenic risk scoring, the validation stage is accomplished by evaluating the algorithm on an independent dataset. The validation stage is essential for ensuring the prediction models do not overfit the training data ([@B23]; [@B58]; [@B1]). Cross validation is a commonly used procedure for validating the models performance using the original dataset ([@B74]; [@B41]; [@B90]; [@B53]; [@B110]). However, external validation (testing) using an independent dataset is required to finally confirm the predictive power of a machine learning model. The utility of the algorithm is finally determined through randomized controlled comparisons to current clinical best practice. Only if the algorithm adds information to more accurately stratify populations, predict disease risk or treatment responses does it ultimately prove its clinical utility.

Factors That Improve the Power of Predictive Models for Complex Diseases
========================================================================

Despite initial promise, the predictive performance of polygenic risk scores for complex diseases has only been moderately successful ([@B97]; [@B41]; [@B1]). A significant contributor to this relatively poor performance revolves about the finding that experimental GWA study data suggests that risk allele contributions to complex diseases have average odds ratios of between 1.1 and 2 ([@B100]). However, GWA studies are typically underpowered and only capable of detecting risk SNPs with odds ratios of \>1.3 ([@B24]; [@B101]). Thus, improving the predictive power of polygenic disease risk models could be as simple as increasing GWA study sample sizes ([@B97]; [@B58]; [@B1]). Rapidly decreasing DNA sequencing costs have led to meta-GWA studies analyzing datasets containing half a million or more samples ([@B87]; [@B5]; [@B46]). The use of larger datasets has increased the frequency of detection of SNPs with small effect sizes. Incorporating SNPs with small effect sizes into polygenic risk models has resulted in an increase in the accuracy of complex disease predictions ([@B97]; [@B39]; [@B90]; [@B1]). It remains likely that this trend to use SNPs identified from bigger datasets will continue into the future, with the associated increases in the accuracy of the resulting risk prediction models.

The size of the training and validation datasets is another critical element in machine learning modeling. However, size is not enough and the datasets must be of high quality with accurate phenotyping that ensures the generalizing predictive power of the resultant machine learning models ([@B90]; [@B96]). [@B98] illustrated the impact of training sample size on the predictive power of a machine learning classification algorithm for inflammatory bowel disease (IBD). The dataset used in the study contained 60,828 individual genotypes from 15 European counties ([@B98]). A machine learning prediction model for Crohn's disease (a subtype of IBD) created from a small subset (*n* = 1,327) of the dataset only performed moderately (AUC = 0.6). However, the predictive power of the model improved consistently with increases in size of the training datasets until the predictive performance reached the maximum (AUC = 0.86) with the full training dataset (*n* = 11,943) ([@B98]).

Technological advances are constantly improving the quality and quantity of the complex integrative datasets that are collected on human phenotypes and disease. Integration of these highly dimensional genomic data within machine learning models can lead to improvements in genetic risk prediction over that achieved for polygenic risk scores ([@B97]; [@B57], [@B58]; [@B41]; [@B29]; [@B38]). Polygenic risk score predictions are based on a linear parametric regression model that incorporates strict assumptions, which include additive and independent predictor effects, a normal distribution for the underlying data, and that the data observations are non-correlated ([@B97]; [@B2]; [@B16]; [@B15]; [@B1]). These assumptions do not necessarily hold true for the fundamental genetic structures of complex polygenic diseases, thus leading to greatly reduced predictive efficacy ([@B97]; [@B2]; [@B16]). Notably, linear additive regression modeling is incapable of accounting for complex interactive effects between associated alleles ([@B2]; [@B16]; [@B58]), which have been reported to make major contributions to phenotypes ([@B30]). Thus, linear additive regression based modeling leads polygenic risk scores toward biased and less effective predictions ([@B18]; [@B35]; [@B16]; [@B58]). By contrast, machine learning algorithms employ multivariate, non-parametric methods that robustly recognize patterns from non-normally distributed and strongly correlated data ([@B97]; [@B57], [@B58]; [@B70]; [@B82]). The capacity of machine learning algorithms to model highly interactive complex data structures has led to these approaches receiving increasing levels of interest for complex disease prediction ([@B97]; [@B57], [@B58]; [@B70]; [@B82]). The strengths and weaknesses of both polygenic risk scoring and predictive machine learning models are summised in [Figure 2](#F2){ref-type="fig"}.
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Machine Learning Feature Selection and Regularization
=====================================================

Data feature selection is the major factor that impacts on a machine learning model's predictive performance ([@B58]). Data feature selection occurs during the machine learning training stage with the aim of reducing data dimensionality, removing noisy and irrelevant data, and thus preserving the most useful signals from the dataset ([@B42]; [@B58]). Data feature selection procedures can be broadly implemented using filtering, embedded modules, or wrapper methods ([@B62]; [@B41]; [@B59], [@B58]; [@B79]). The choice of selection procedures depends on the original data attributes and prediction model criteria ([@B62]; [@B58]). For complex polygenic diseases, SNPs are currently considered the most informative data features within genotype data ([@B2]; [@B59]; [@B98]; [@B79]). It is assumed that the SNPs that are selected for inclusion in the predictive models are associated with loci that contribute mechanistically to the underlying disease etiology ([@B62]; [@B58]; [@B45]). Despite this, how the SNP mechanistically contributes to the disease may not be understood. Commonly, in the first stage of the model building, variants within the genotype data are filtered and subdivided into groups according to their GWA study *P*-value thresholds ([@B97], [@B98]; [@B59], [@B58]; [@B52]). Embedded methods are implemented inside the model building algorithm and function to select SNPs following the detection of their interactive effects ([@B59]) and thus enable incorporation of only informative SNPs into the predictors ([@B102]; [@B59]; [@B98]). Wrappers serve the same purpose as embedded methods. However, wrappers are independent stand-alone SNP selection modules implemented before the model building process ([@B61]; [@B59]).

Overfitting is a phenomenon whereby models are so closely fitted to a dataset and they cannot be used to generalize to other datasets. The chances of overfitting models can be reduced by regularization, which is a process that maximizes the generalized predictive power of machine learning models ([@B88]; [@B111]; [@B58]). For example, the two most common types of regression-based regularization are L1 and L2. L1 and L2 regularizations both use a penalized loss function to assign weights that adjust data feature effects and reduce the complexity of the regression models ([@B88]; [@B111]; [@B58]). L1 regularization sets the weights of non-informative data features to zero, thus eliminating effects and allowing only essential and valuable data feature effects to be included into the machine learning regression modeling ([@B88]; [@B111]; [@B58]). By contrast, L2 regularization minimizes non-essential data features using non-zero weights ([@B88]; [@B111]; [@B58]). As a result of this, L2 regularization is not typically used for feature selection.

Regression-based L1-regularization is one of the most commonly used machine learning feature selection methods, with Lasso and Elastic Net currently being the most popular L1 regularization modules ([@B88]; [@B111]; [@B102]; [@B58]). There are many examples where L1-regularization has enhanced the machine learning algorithm's predictive performance for different diseases ([@B2]; [@B98]; [@B81]; [@B80]). For example, [@B98] implemented a two-step model training process in the development of an L1-regularized algorithm for Crohn's disease prediction. Firstly, the Lasso-logistic regression method identified a set of essential and informative SNPs. Subsequently, the selected SNPs were applied to a SVM and a logistic predictor for Crohn's disease. Following SNP optimization by L1-regularization, both the non-parametric and parametric predictors achieved similar results with an AUC = 0.86 compared to an AUC = 0.73 for the simple polygenic risk score.

[@B3] used six European genotype datasets to develope a Lasso--SVM integrated model, with an AUC = 0.9, for CD. Following data cleaning and adjustment for population structure effects by principal components, [@B3] created a L1-SVM predictor from each dataset with cross-validaion. They then used the other five datasets for external validation. Data feature selection for all the predictors was acomplished by the Lasso method embedded within the SVM algorthm. The best predictor that was generated had an AUC = 0.9 and its clinical utility is being explored for CD prediction ([@B1]). Notably, the identification of the essential SNPs by the Lasso-SVM model has provided insights that will help decipher the genetic basis underlying the etiologic pathways of CD pathogenesis.

Supervised Learning Algorithms
==============================

Supervised learning algorithms can be classified as regression-based or tree-based methods ([Table 1](#T1){ref-type="table"}; [@B23]; [@B58]). Logistic regression, linear regression, neural networks, and SVM are popular examples of regression based supervised learning algorithms ([@B23]; [@B41]). Regression-based supervised learning methods employ polynomial parametric or non-parametric regression methods to map the associations of multidimensional input data to outputs ([@B23]; [@B58]; [@B49]). By contrast, tree-based supervised learning algorithms, which include Decision trees and Random forests, typically utilize binary decision splitting rule approaches to model the relationships between the input and output data ([@B23]; [@B58]; [@B49]).

###### 

A brief view of common machine learning algorithms.

  Regression based                      Examples                                                                                                                                
  ------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------- -------------------------
  Logistic regression                   • Use parametric regressions to estimate the probabilities of dichotomous outputs ([@B23])                                              [@B20]; [@B105]; [@B55]
  Neural Network                        • Use multi-layers of non-parametric regressions and transformations to model input data to outputs ([@B49])                            [@B71]; [@B52]; [@B103]
  Support vector machine (SVM)          • Use non-parametric regressions to model input data for creating multi-dimensional hyperspaces to discriminate the outputs ([@B106])   [@B19]; [@B3]; [@B32]
  **Regression based regularization**                                                                                                                                           
  Lasso                                 • Apply L1 penalized loss functions in regression ([@B58])                                                                              [@B88]; [@B98]; [@B85]
  Elastic net                           • Apply L1 and L2 penalized loss functions in regression ([@B58])                                                                       [@B111]; [@B2]; [@B68]
  **Tree-based**                                                                                                                                                                
  Decision tree                         • Utilize binary decision splitting rule approaches to model the relationships between input data and outputs ([@B49])                  [@B66]; [@B31]; [@B44]
  Random forest                         • Utilize an ensemble of randomized decision trees to model input data to outputs ([@B49])                                              [@B12]; [@B99]; [@B22]

The examples include the founding papers and current examples as at December 2018

.

Regression-based machine learning approaches have been widely employed in risk prediction for many diseases including: cancer; Alzheimer's; cardiovascular disease; and diabetes ([@B13]; [@B21]; [@B63]; [@B106]; [@B108]). For example, an SVM regression-based non-parametric machine learning model of the genetics of type 1 diabetes was built and trained from 3443 individual genotype samples ([@B50]) achieving an AUC = 0.84, which is significantly higher than the polygenic risk scoring model AUC = 0.71 ([@B18]; [@B97]; [@B39]). Notably, validation testing confirmed that the predictive power of the non-parametric SVM consistently outperformed the logistic regression control prediction model on two independent datasets ([@B97]).

Deep learning prediction models developed from neural network algorithms have been gaining a lot of interest following their successful implementation in image recognition and natural language processing applications ([@B33]; [@B104]). In genomics, deep learning applications are helping to identify functional DNA sequences, protein binding motifs and epigenetic marks ([@B4]; [@B110]; [@B109]). A deep learning model incorporating SNPs associated with obesity has demonstrated a remarkable ability to correctly identify a case out of a randomly chosen pair of case and control samples with an AUC = 0.99 ([@B52]). After data cleaning, a genotype dataset of 1997 individuals including 879 cases and 1118 controls with 240,950 SNPs was obtained. The dataset was subsequently filtered into four SNP feature sets, according to *P*-value thresholds obtained from the GWA study. The numbers of SNPs in the feature sets were: 5 (*P*-value: 1 × 10^-5^); 32 (*P*-value: 1 × 10^-4^); 248 (*P*-value: 1 × 10^-3^); and 2465 (*P*-value: 1 × 10^-2^). The feature set with 2465 SNPs (*P*-value: 1 × 10^-2^) was used to construct an artificial neural network (ANN) deep learning model from 60% of the original genotypes as training, 20% as internal validation, and 20% as testing. The ANN deep learning model delivered a significant predictive performance for obesity on the testing set with an AUC = 0.9908 ([@B52]). [@B52] clearly demonstrated the ability of the ANN deep leaning algorithm to capture combined SNP effects and predict complex polygenic diseases.

Tree-based machine learning commonly uses a Random Forest algorithm ([@B36]; [@B11]; [@B89]; [@B45]). Random Forest algorithms construct prediction models using an ensemble method with many decision trees. Specifically, Random Forest algorithms select for and evaluate SNPs that are informative in the decision-tree building process ([@B11]; [@B53]). A strength of Random Forest models is their ability to effectively handle missing and highly dimensional data structures that contain complex interactions ([@B11]; [@B53]). For example, in a recent study a Random Forest algorithm was used to predict T2D risk, outperforming both SVM, and logistic regression models ([@B45]). In this study, a set 1074 individual genotypes and 101 preselected T2D related SNPs were collected and cleaned. The cleaned data (677 samples with 96 related SNPs) were fed into a Random Forest learning algorithm and produced a T2D predictor that delivered an AUC = 0.85 with cross validation ([@B45]). In so doing, the Random Forest model also refined the preselected SNPs to identify a subset that are strongly associated with T2D and can be used to interrogate the etiology of the disease ([@B11]; [@B53]; [@B45]). The implementation of Random Forrest is still useful as a machine learning method for complex disease risk modeling ([@B11]; [@B17]; [@B8]; [@B45]).

Individual Tissue-Specific Heterogeneity
========================================

Although PRS and machine learning approaches have been extensively used in complex disease prediction, little attention has been given to the utility of machine learning applications in calculating tissue-specific disease risk in individuals. This is largely because GWAS studies identify relationships between global somatic SNPs and their associated phenotypes ([@B93]). However, GWAS-identified, disease-associated SNPs are recognized as modifying regulatory mechanisms which affect gene expression in a tissue-specific manner ([@B64]; [@B6]). Therefore, by expanding GWAS methodology to include expression measures (i.e., expression quantitative trait locus, eQTL), genetic analyses could help to interrogate the inter-related biological networks between cell and tissue types that propagate the causal effects to complex diseases ([@B6]; [@B60]). For example, incorporating eQTL data led to the identification of adipose-specific gene expression patterns that could have an inferred causal role in obesity ([@B54]). Similarly, genes with liver specific expression are now thought to be a major contributor to T2D ([@B72]). By extending eQTL analyses to include chromatin spatial interaction (Hi-C) data, it was shown that T2D and obesity associated SNPs have spatial-eQTLs which implicate dysfunction of specific regulatory actions in various tissue types ([@B27]). These studies strongly suggest that by aggregating biological data types (e.g., DNA, RNA, and epigenetic data), the accumulated result becomes a tissue-specific network analysis of associated dysfunctionally regulated genes. Thus, specific disease risk to individuals should be calculated using a tissue-by-tissue approach, concluding with tissue-specific networks and pathways that are particular to the development of a disease.

In so doing, it may be possible to leverage the tissue-effect heterogeneity of patients by identifying the correct genes and tissue loads to provide essential targets for potential therapeutic interventions leading to enhanced therapeutic effectiveness. The tissue-effect heterogeneity could also help to recognize individual subtypes of complex disease, facilitating personalized treatments. By targeting the causal associated SNP tissue-specific effects, predictions of patient specific tissue-effect disease risks could provide informative biomarkers for early disease prevention, bringing about a substantial reduction of later disease burdens and costs. [@B110] have utilized the deep learning algorithm to predict the functional effects of non-coding variants by modeling the pattern of genomic and chromatin profiling information. They have been able to employ this method to distinguish important eQTLs and disease-related SNPs from various eQTL and SNP databases. Nevertheless, despite the immense promise of machine learning, it is important to recognize that at present there is insufficient research in their application for the identification of disease-associated tissue-specific risks. It is likely that these caveats will be attenuated in the near future through advanced tissue-specific studies of complex traits and disease.

Conclusion
==========

Precision medicine is a rapidly advancing field that already provides customized medical treatments and preventative interventions for specific diseases, especially cancer. Using a patient's SNPs to predict individual disease risks is an essential element for delivering the fuller promise of precision medicine. Polygenic risk scoring is a straightforward model for assigning genetic risk to individual outcomes, but has achieved only limited success in complex disease predictions due to its dependency on linear regression. The polygenic risk scoring method is ineffective in modeling highly dimensional genotype data with complex interactions. By contrast, the strength of machine learning data modeling in complex disease prediction lies in its handling of interactive high-dimensional data. Coupled with large new population datasets with high-quality phenotyping at different stages in the lifecourse, machine learning models are capable of classifying individual disease risks with high precision. Notably, machine learning predictors that include tissue-specific disease risks for individuals show even greater promise of insights that could ultimately provide cost-effective and proactive healthcare with great efficacy.
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